Histone Deacetylase Inhibitors in Cancer: What Have We Learned?
James R Whittle, Jayesh Desai
Cancer | WILEY-BLACKWELL | Published : 2015
The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single-agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.